Why the Pancreatic Cancer Drug Daraxonrasib Changes Everything
A KRAS-inhibitor pill called daraxonrasib produced near-complete tumor disappearance in some patients with advanced pancreatic cancer — the deadliest common malignancy. But the trial’s small size and short follow-up raise critical questions about durability.
The Number That Should Set Oncologists on Fire
Sixty-one patients. About one in twelve walked away with tumors so small they disappeared from CT scans entirely. In the world of pancreatic cancer — a disease where 50 percent of people die within three months of diagnosis and the five-year survival rate hovers around 3 percent for metastatic disease — that single fraction is a statistical anomaly worth dissecting.
The drug is daraxonrasib. It targets KRAS, the mutated oncogene that drives roughly nine in ten pancreatic tumors. Presented at the EORTC-NCI-AACR Symposium in Barcelona by Dr. Wungki Park of Memorial Sloan Kettering, the Phase I/II trial results read like something that arrived too early: a 90 percent disease-control rate, a 61 percent tumor-shrinkage rate, and a one-year survival of 76.6 percent — versus the 40 to 45 percent baseline typically seen with standard chemotherapy regimens.
Park called it “the closest to cure” he has ever witnessed in spread pancreatic cancer. Michelle Mitchell of Cancer Research UK called it “the biggest leap forward we’ve seen in decades.” Both are measuring against a backdrop of extraordinary despair. Pancreatic cancer kills more people than breast and bowel cancer combined in the UK, yet receives a fraction of research funding. A therapy that flips survival curves even modestly warrants the hype — and scrutiny it simultaneously invites.
Why KRAS Was Considered Undruggable
The KRAS protein sits at a critical junction in cellular signaling, relayig growth and division instructions from the cell surface to the nucleus. When mutated — most commonly at codon G12D in pancreatic cancer — KRAS locks into a perpetually active state. Tumors become addicted to its output. Decades of drug-discovery attempts failed because KRAS lacked the classic pockets and binding sites that small-molecule inhibitors require.
That changed in 2021 with sotorasib, which specifically targets the KRAS G12C mutation. G12C accounts for roughly 27 percent of lung cancers and 3 to 8 percent of colorectal cancers. Pancreatic cancer, however, overwhelmingly carries G12D — a mutation sotorasib cannot touch.
Daraxonrasib appears to be a next-generation inhibitor capable of engaging both variants. That is a dramatic expansion of the addressable population. If confirmed, it moves KRAS inhibition from a niche lung-cancer therapy into a platform that could reshape treatment across dozens of tumor types — from pancreatic to colorectal to non-small-cell lung cancer — all driven by the same fundamental molecular vulnerability.
What the Trial Actually Shows (and Doesn’t)
The trial enrolled patients with advanced, metastatic disease — exactly the population doctors traditionally consider untreatable with curative intent. Over a median follow-up of 18 months, 90 percent of the 61 participants experienced halted tumor growth, 61 percent saw shrinkage, and about 8 percent (five individuals) reached undetectable disease on imaging.
These are impressive response rates for any solid tumor. They are anomalous in pancreatic cancer. The one-year survival rate of 76.6 percent is roughly double what historical controls achieve with gemcitabine plus nab-paclitaxel, the current backbone of first-line treatment. No randomized controlled trial underpins these numbers. This is a single-arm, open-label study — the kind of evidence that generates excitement in conference halls but rarely satisfies regulators seeking approval on its own merit.
The most important missing variable is durability. None of the patients in this trial received prior KRAS inhibitor therapy. Every KRAS inhibitor studied to date — sotorasib, adagrasib, and several next-generation compounds — encounters eventual resistance. Tumors re-emerge through secondary mutations in KRAS itself, bypass-pathway activation, or phenotypic switching. Without knowing how long the five undetectable cases remain clear, it is impossible to separate true remission from temporary suppression.
Longer studies are underway. But 18 months of median follow-up in an 18-month-old trial means there is very little data on events past the first year. If the undetectable tumors recur at month 24 or month 30 — as happens frequently with KRAS inhibitors — the headline shrinks considerably.
Who Wins, Who Loses, and What Comes Next
Patients with advanced pancreatic cancer are the immediate winners, regardless of caveats. Even a partial response that buys additional months of meaningful life changes trajectories that previously offered nothing. The emotional weight of hearing that your tumor shrank — or vanished — in a disease where standard options routinely fail is immeasurable.
Pharmaceutical companies stand to gain enormously. The KRAS-inhibition market is projected to exceed several billion dollars annually by decade’s end. Daraxonrasib’s developer, presumably backed by a major partner, faces the classic binary: deliver durable responses and reap blockbuster revenues, or stall on resistance and watch competitors leap ahead.
Regulators are the gatekeepers. The US Food and Drug Administration has used the accelerated-approval pathway for breakthrough oncology drugs before, granting conditional authorization based on surrogate endpoints and then requiring confirmatory trials. European regulators tend to demand more mature data before full approval. Either way, Phase III data — ideally a randomized comparison against standard chemotherapy — remains essential before daraxonrasib reaches routine clinical use anywhere in the world.
The broader cancer community stands to win if daraxonrasib’s mechanism proves broadly effective across KRAS-mutant tumors. Pancreatic cancer’s 90 percent KRAS mutation rate makes it an ideal proof-of-concept indication. Success here validates the entire KRAS-targeting approach and accelerates development for lung, colorectal, and thyroid cancers where these mutations also drive disease.
But there is a risk of overextension. The media narrative around daraxonrasib already treats “breakthrough” as synonymous with “cure.” Medical oncologists who present this data carefully must constantly push back against inflated expectations. A 76 percent one-year survival rate in a population historically destined to die within months is genuinely transformative. It is not yet a cure.
The Real Stakes: Beyond the Headlines
What separates daraxonrasib from previous KRAS inhibitors is depth, not just breadth. Sotorasib produced objective response rates in the 30 to 40 percent range in lung cancer — respectable but far from transformative. Daraxonrasib’s 61 percent response rate and eight complete-disappearance cases suggest a qualitatively different interaction with the mutant protein. That difference may reflect superior target engagement, better intratumoral penetration, or a distinct binding mode that evades the resistance mechanisms that limit earlier agents.
Understanding why daraxonrasib outperforms its predecessors matters more than celebrating the headline numbers. The next round of trials will test combination strategies — pairing daraxonrasib with immune checkpoint inhibitors, with KRAS downstream blockers, or with conventional chemotherapy. Early evidence suggests that KRAS inhibition alone eventually yields to adaptive resistance. Combinations that attack the tumor from multiple angles simultaneously are the logical next step, and arguably the only path toward durable remission.
For now, daraxonrasib represents a genuine inflection point in a disease that has resisted meaningful therapeutic progress for decades. The trial results are compelling enough to justify rigorous Phase III testing and urgent questions about resistance mechanisms. They are not compelling enough to declare victory. In pancreatic cancer, declaring victory prematurely has always been the more dangerous error.